Summary
Prednisolone Sodium Phosphate has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Asthma would be drug repurposing rather than first-in-human development. This does not mean it is approved for Asthma. ClinicalTrials.gov lists 8 registered trials linking Prednisolone Sodium Phosphate to Asthma: 3 have completed; 5 are terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 4 (NCT04276233). The largest enrolment is 192 participants (NCT05850143). Registration activity spans 2009 to 2023. The literature layer holds 1 publication for this pair: 1 clinical trial publication. The dated items are from 2007. These are primary trial reports rather than syntheses, so results have not yet been pooled or graded independently.
The RepurpOS disease-intelligence file for Asthma ranks 642 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: 26% of childhood-onset asthma in clinical remission by adulthood; <20% adult-onset achieves sustained remission; 65% long-term remission in mild-moderate vs 16% in severe.
Evidence table
| Evidence tier | A · Strong |
|---|---|
| Evidence score | 40.0 (trials 18.0, literature 2.0, tier 15, approved bonus 5.0) |
| Registered trials | 8 total: 0 recruiting, 0 active / not yet recruiting, 3 completed, 5 other |
| Linked publications | 1 (1 clinical trial publication) |
| Agent type | Drug (Small molecule) |
| Development stage (any indication) | Approved |
| Mechanism / class | Not recorded |
| Data sources | Open Targets, ChEMBL |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
| NCT ID | Title | Status | Phase | Enrolment |
|---|---|---|---|---|
| NCT01326494 | Reducing the Acute Care Burden of Childhood Asthma on Health Services in British Columbia 2011 | completed | Phase 4 | 92 |
| NCT04276233 | Efficacy and Safety Study of Mepolizumab 100 Milligram (mg) Subcutaneous (SC) in Indian Participants Aged Greater Than or Equal to (>=) 18 Years With Severe Eosinophilic Asthma 2021 | completed | Phase 4 | 100 |
| NCT03133897 | Dexamethasone Versus Prednisone for Asthma Treatment in the Pediatric Inpatient Population; a Feasibility Study 2018 | terminated | Phase 3 | 20 |
| NCT01615874 | Study of the Effect of Mometasone Furoate/Formoterol (MF/F), Montelukast and Beclomethasone Dipropionate (BDP) on Plasma Cortisol Levels of Children 5-11 Years Old With Persistent Asthma (P05574) 2013 | withdrawn | Phase 2 | — |
| NCT04874610 | Steroid Metabolism in Obese and Non-Obese Pediatric Patients Hospitalized for Status Asthmaticus 2021 | completed | Not applicable | 15 |
| NCT06171932 | Comparison Of Efficacy Of Hydrocortisone And Methyl Prednisolone In Acute Severe Asthma 2023 | status unknown | Not applicable | 60 |
| NCT05850143 | EFFECTIVENESS OF SINGLE DOSE ORAL DEXAMETHASONE VERSUS MULTIDOSE PREDNISOLONE FOR TREATMENT OF ACUTE EXACERBATIONS OF ASTHMA AMONG CHILDREN ATTENDING THE EMERGENCY DEPARTMENT OF CHILDREN HOSPITAL, ISLAMABAD 2019 | status unknown | Not applicable | 192 |
| NCT00971893 | A Study To Assess The Safety And Effectiveness Of Medrol® In Acute Asthma In Indian Patients 2009 | withdrawn | Not applicable | — |
Published literature
- Clinical trial publication Prednisolone oral solution plus inhaled procaterol for acute asthma in children: a double-blind randomized controlled trialHuang LH, Shyur SD, Wen DC et al. · Acta paediatrica Taiwanica = Taiwan er ke yi xue hui za zhi · 2007 · PMID 18254574
Mechanism and notes
No mechanism of action is recorded for this pair in the source databases.
OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in Open Targets and ChEMBL. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Prednisolone Sodium Phosphate approved for Asthma?
Prednisolone Sodium Phosphate has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Asthma would be drug repurposing rather than first-in-human development. This does not mean it is approved for Asthma. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Prednisolone Sodium Phosphate in clinical trials for Asthma?
ClinicalTrials.gov lists 8 registered trials linking Prednisolone Sodium Phosphate to Asthma: 3 have completed; 5 are terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 4 (NCT04276233). The largest enrolment is 192 participants (NCT05850143). Registration activity spans 2009 to 2023.
What does the evidence show for Prednisolone Sodium Phosphate in Asthma?
Prednisolone Sodium Phosphate has 3 completed trials and 1 linked publication for Asthma. Completed trials may or may not have posted results; follow the NCT links to check. OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in Open Targets and ChEMBL. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-05. Page built 2026-10-07.